641. Evaluation of the FilmArray Pneumonia Panel and Potential Impact of Antimicrobial Use on Patients in a Trauma and Medical Intensive Care Unit Kary Krupinski-Shaw, BS; Lauren Lopez, PharmD, BCPS, BCIDP; Halle Orlinski, PharmD; Patrick Orboit, MS, MT(ASCP); Stella Antonara, PhD, D(ABMM); OhioHealth Laboratory Services, Columbus, Ohio; ProMedica Toledo Hospital, Toledo, Ohio

Session: 67. New Diagnostics Thursday, October 3, 2019: 12:15 PM

Background. Organisms causing infections of the lower respiratory tract in hospitalized patients can lead to high morbidity and mortality. Identification of the agents of pneumonia allows implementation of appropriate antimicrobial therapy and fast and accurate results are essential for the application of the correct antimicrobial regimens.

Methods. For 6 months results of quantitative bronchoalveolar lavage (Q-BAL) respiratory cultures, ordered as a standard of care for patients in our intensive care unit, were compared with the results obtained by a new multiplex molecular assay for the detection of lower respiratory tract pathogens, the FilmArray pneumonia panel (PP). The panel offers semi-quantitation of the bacterial targets that were compared with the quantitative results of the Q-BALs. Additionally, a retrospective chart review was performed to examine whether there would be any difference in the timing of appropriate antimicrobial therapy if the results of the panel were to be available for those patients. Appropriate antimicrobial therapy was determined according to the institutional protocol for treatment of patients for ventilator-associated pneumonia based on the results of the quantitative cultures.

Results. Thirty-six unique patients Q-BALs were run and of those there was 82% agreement on the detected targets between cultures and PP. Six targets were not detected by the panel (yeast, S. maltophilia, Streptococcus, Salmonella spp.), M. catarrhalis, S. agalactiae and 3 viral targets were detected only by the panel. There was 100% agreement between the panel detected resistance markers and the culture isolates susceptibilities. Of the Q-BAL cultures, 12 were excluded because their medical records were not available for review. Of the 24 reviewed, 8 (33.3%) would have de-escalation in their antibiotics use at least 24h earlier due to the PP result. Eight (33.3%) would have no potential change in therapy and 8 (33.3%) could have inappropriate escalation or continuation due to reporting of potential pathogens by the PP but recorded as normal flora by cultures.

Conclusion. The use of PP would lead to a reduction of unnecessary antimicrobial therapy in 1/3 of the patients examined. However, quantification of organisms otherwise reported as normal flora may lead to unnecessary treatment and requires education of staff to understand the results of the assay.

Disclosures. All authors: No reported disclosures.

642. Higher Diagnostic Accuracy with Ultrasensitive Detection of Helicobacter pylori Stool Antigen Using Single-Molecule Counting Technology Phoebe Katzenbach, BS; Gipsa Dave, MS; Ali Mukherjee, PhD; Johanna Sandlund, MD, JD; Joel Estis, MS; Niamh Nolan, MS; Niaz Banai, MD; Brian Noland, PhD; Singulex Inc., Alameda, California; Stanford University School of Medicine, Palo Alto, California

Session: 67. New Diagnostics Thursday, October 3, 2019: 12:15 PM

Background. Current diagnostic methods for Helicobacter pylori infection include fecal antigen tests, 1C-urea breath test, and gastric biopsy. The breath test is limited by poor specificity and the fecal antigen tests by poor sensitivity. We have developed a prototype assay for detection of H. pylori antigen in human stool, powered by ultrasensitive Single Molecule Counting technology, and compared the analytical performance to a commercially available enzyme-linked immunosassay (ELISA) antigen test.

Methods. The Singulex Clarity H. pylori antigen assay incubates diluted stool with capture and fluorescent-labeled detection antibodies. After incubation and wash steps, fluorescent molecules are eluted and single-molecule fluorescence measured by detected events (DE). Analytical performance was compared with a commercial ELISA (Premier Platinum HpSA Plus, Meridian Bioscience, Inc.) using serial dilutions of H. pylori control (~37,500–1.7 ng/mL) and high positive stool (signal to noise ratio >2). Clinical performance was evaluated using two cohorts, one had 10 ELISA-negative and 10 ELISA-positive samples and the other 13 positive (> 500 at 450/630) and 5 low positives near the ELISA cutoff (0.100–0.500 at 450/630). One sample was excluded due to discordant ELISA results, and three to reader flags.

Results. The lower limit of detection of the Clarity H. pylori assay was 1.7 ng/mL and the ELISA 1,250 ng/mL (IFU: LOD 4.6 ng/mL). A high positive stool sample was detected by the Clarity H. pylori assay diluted 1:1,000,000 and by the ELISA 1:10,000. The Clarity H. pylori assay showed a 729-fold increase in lower limit of detection and 1,000-fold increase in endogenous antigen lower limit of detection compared with the ELISA. Clarity signal ranged from 46–665 DE for ELISA-negative samples and 487,484–576,742 DE for ELISA-positive samples.

Conclusion. The Singulex Clarity H. pylori antigen assay may have orders of magnitude higher analytical sensitivity than the commercial ELISA and demonstrated 100% positive agreement and 100% negative agreement on detection of H. pylori antigen in human stool samples. The ultrasensitive Clarity H. pylori assay has the potential for high sensitivity and specificity to improve current diagnostic options for H. pylori infection; however, additional multicenter studies are required.

Disclosures. All authors: No reported disclosures.

643. Comparison of Multiplex Polymerase Chain Reaction (PCR) and Routine Culture for the Detection of Respiratory Pathogens in Pneumonia Patients Emad Abu Sitta, MD; Nicole Hubbard, MD; Geetha Suleyman, MD; University of Toledo Medical Center, Toledo, Ohio; Promedica Toledo Hospital, Toledo, Ohio

Session: 67. New Diagnostics Thursday, October 3, 2019: 12:15 PM

Background. The identification of causative pathogens in pneumonia can be challenging, and conventional culture methods can take up to 72 hours. However, rapid molecular tests identify organisms within hours. The BioFire FilmArray (bioMérieux, North Carolina) Pneumonia Panel was recently approved by the FDA. The multiplex PCR system identifies 33 targets from sputum and bronchoalveolar (BAL) samples, which include 18 bacteria, 8 viruses, and 7 antibiotic resistance genes. The purpose of this study was to compare the panel to routine culture methods for the detection of respiratory pathogens in patients with pneumonia in a 794-bed teaching hospital in northwest Ohio.

Methods. We retrospectively screened all hospitalized intensive care unit patients who met clinical and radiological criteria of pneumonia using electronic medical records between November 2018 and February 2019. Adult patients who had respiratory cultures collected within 7 days were included. Repeat specimens were excluded. Routine cultures were performed using the laboratory’s standard procedure, and Pneumonia Panel testing was performed according to manufacturer instructions. The use of PP would lead to a reduction of unnecessary antimicrobial therapy in 1/3 of the patients examined. However, quantification of organisms otherwise reported as normal flora may lead to unnecessary treatment and requires education of staff to understand the results of the assay.

Disclosures. All authors: No reported disclosures.

644. Comparative Evaluation of ETEST® ERV bioMérieux with the CLSI Broth Microdilution Method for Eravacycline MIC Determination Veronique Sauvonnert1; Corey Fyfe, MS2; Diane Halimi1; Roland Martelin2; Gilles Zambardi1; Biomerieux, La Balme Les Grottes, Rhone-Alpes, France; Tetracapharmaceuticals, Watertown, Massachusetts

Session: 67. New Diagnostics Thursday, October 3, 2019: 12:15 PM

Background. Eravacycline (XERAVA®) is a novel, FDA and EMA-approved fully-synthetic fluorocycline antibiotic developed by Tetracapharmaceuticals Inc. for the treatment of complicated intra-abdominal infections (cIAI) including those caused by multidrug-resistant (MDR) pathogens that have been highlighted as urgent public health threats by the US CDC and the WHO.

• The new ETEST ERV strip (MIC range 0.002 – 32 µg/mL) has been developed by bioMérieux and calibrated vs. the broth microdilution reference method (BMD) as described by the Clinical and Laboratory Standards Institute (CLSI) to determine the minimal inhibitory concentration (MIC) of eravacycline against Enterobacterales and Enterococci. The aim of the study was to compare ETEST ERV to the CLSI BMD method on a panel of 166 strains comprising 131 Enterobacterales and 35 Enterococci.

Methods. Quality control was performed with the CLSI QC strains E.coli ATCC 25922 and E.faecalis ATCC 29212. The ETEST ERV strip was applied on a Mueller–Hinton agar plate previously seeded with a 0.5 McF bacteriostatic suspension. After incubation for 16–20H at 35°C, the reading was performed using the bacteriostatic mode i.e., 80% of growth. The FDA-approved breakpoints were applied (≤0.5µg/mL for Enterobacterales and ≤0.064 µg/mL for Enterococci).

Results. The MIC essential agreement was 99.4% at ±1 dilution for the whole panel and the category agreement was 98.4% with 4.8% Major Errors (1 E. coli, 2 K. pneumoniae, 1 K. aerogenes, 1 C. koseri, 1 E. faecalis), all at ±1 dilution around the single breakpoint. No Very Major Error (VME) was observed.

Conclusion. In this study, the new ETEST ERV strip has been found to be substantially equivalent to the CLSI reference method. MIC end-points appear easier to read in comparison to the reference method. With a 15-dilution MIC range and simplicity of use, ETEST ERV could represent a valuable tool for MIC determination and an alternative to the BMD reference method. ETEST ERV will undergo clinical studies to seek FDA clearance and CE marking. For Research Use Only. The performance characteristics of this product have not yet been established.

Disclosures. All authors: No reported disclosures.

645. Singulex Clarity Norovirus Assay (In Development) Provides Ultrasensitive Detection of Norovirus Genogroups I and II Gipsa Dave, MD; Phoebe Katzenbach, BS; Johanna Sandlund, MD; Joel Estis, MS; Ali Mukherjee, PhD; Niamh Nolan, MS;